Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 19/20 | 0.66 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8600009 | 0.84 | ALOX5 (0.62) | ALOX5NR1I2 | |
| Succinic Acid SCHEMBL705370 | 0.83 | GSTO1 (0.67) | ALOX5NR1I2 | |
| SCHEMBL4779257 | 0.82 | ALOX5 (0.51) | ALOX5NR1I2PPARGPPARA | |
| SCHEMBL6028033 | 0.81 | ALOX5 (0.58) | ALOX5NR1I2 | |
| SCHEMBL6463246 | 0.81 | ALOX5 (0.58) | ALOX5NR1I2 | |
| SCHEMBL6027939 | 0.81 | ALOX5 (0.58) | ALOX5NR1I2 | |
| SCHEMBL5806822 | 0.81 | ALOX5 (0.57) | ALOX5NR1I2 | |
| SCHEMBL407517 | 0.81 | AKT1 (0.65) | ALOX5NR1I2PPARGPPARA | |
| SCHEMBL8747773 | 0.81 | ALOX5 (0.56) | ALOX5 | |
| SCHEMBL3270839 | 0.81 | AKT1 (0.65) | ALOX5NR1I2PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119117-B2 | Tocopherol enriched compositions and amelioration of inflammatory symptoms | GALILEO PHARMACEUTICALS, INC. (US) | 2006-10-10 | — | — | US | claimed |
| US-7081476-B2 | Tocopherol enriched compositions for reducing IL6 levels | GALILEO PHARMACEUTICALS, INC. (US) | 2006-07-25 | — | — | US | claimed |
| US-20050124689-A1 | Tocopherol enriched compositions and amelioration of inflammatory symptoms | CHENANGO ZERO LLC | 2005-06-09 | — | — | US | claimed |
| US-20170296505-A1 | LONG-CHAIN CARBOXYCHROMANOLS AND ANALOGS FOR USE AS ANTI-INFLAMMATORY AGENTS | PURDUE RESEARCH FOUNDATION (US) | 2017-10-19 | — | — | US | disclosed |
| US-9676744-B2 | Long-chain carboxychromanols and analogs for use as anti-inflammatory agents | PURDUE RESEARCH FOUNDATION (US) | 2017-06-13 | — | — | US | disclosed |
| US-20150073044-A1 | LONG-CHAIN CARBOXYCHROMANOLS AND ANALOGS FOR USE AS ANTI-INFLAMMATORY AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-03-12 | — | — | US | disclosed |
| US-8822529-B2 | Long-chain carboxychromanols and analogs for use as anti-inflammatory agents | PURDUE RESEARCH FOUNDATION (US) | 2014-09-02 | — | — | US | disclosed |
| EP-1691759-A4 | PLANT-DERIVED PROTEIN EXTRACT COMPOSITIONS AND METHODS | JOHNSON & JOHNSON CONSUMER (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1418904-A4 | TOCOPHEROL ENRICHED COMPOSITIONS AND AMELIORATION OF INFLAMMATORY SYMPTOMS | JOHNSON & JOHNSON CONSUMER (US) | 2007-11-21 | — | — | EP | disclosed |
| US-7119117-B2 | Tocopherol enriched compositions and amelioration of inflammatory symptoms | GALILEO PHARMACEUTICALS, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1691759-A2 | PLANT-DERIVED PROTEIN EXTRACT COMPOSITIONS AND METHODS | Galileo Pharmaceuticals, Inc. (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20050137253-A1 | Formulations and methods for treatment or amelioration of inflammatory conditions | JOHNSON & JOHNSON CONSUMER INC. | 2005-06-23 | — | — | US | disclosed |
| US-20050124689-A1 | Tocopherol enriched compositions and amelioration of inflammatory symptoms | CHENANGO ZERO LLC | 2005-06-09 | — | — | US | disclosed |
| WO-2005048929-A2 | PLANT-DERIVED PROTEIN EXTRACT COMPOSITIONS AND METHODS | GALILEO PHARMACEUTICALS, INC. (US) | 2005-06-02 | — | — | WO | disclosed |
| US-20050112078-A1 | Plant-derived protein extract compositions and methods | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2005-05-26 | — | — | US | disclosed |
| EP-1418904-A2 | TOCOPHEROL ENRICHED COMPOSITIONS AND AMELIORATION OF INFLAMMATORY SYMPTOMS | Galileo Laboratories, Inc. (US) | 2004-05-19 | — | — | EP | disclosed |
| US-20040048919-A1 | Compositions and methods for reduction of inflammatory symptoms and/or biomarkers in female subjects | ALLOY VENTURES, INC. | 2004-03-11 | — | — | US | disclosed |
| US-20030144219-A1 | Formulations and methods for treatment or amelioration of inflammatory conditions | JOHNSON & JOHNSON CONSUMER INC. | 2003-07-31 | — | — | US | disclosed |
| US-20030100603-A1 | Tocopherol enriched compositions and amelioration of inflammatory symptoms | JOHNSON & JOHNSON CONSUMER INC. | 2003-05-29 | — | — | US | disclosed |
| WO-2003015494-A2 | TOCOPHEROL ENRICHED COMPOSITIONS AND AMELIORATION OF INFLAMMATORY SYMPTOMS | GALILEO PHARMACEUTICALS, INC. (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144219-A1 | Formulations and methods for treatment or amelioration of inflammatory conditions | ALOX15B, ALOX5, ALOX12 | ALOX5 2/4885NR1I2 1261/4885PPARG 43/4885 |
| US-20040048919-A1 | Compositions and methods for reduction of inflammatory symptoms and/or biomarkers in female subjects | PGR, PTGES3, PGRMC1 | ALOX5 13/4885NR1I2 755/4885PPARG 158/4885 |
| US-20050124689-A1 | Tocopherol enriched compositions and amelioration of inflammatory symptoms | TTPA, TNNT2, GSR | ALOX5 35/4885NR1I2 823/4885PPARG 68/4885 |
| US-20150073044-A1 | LONG-CHAIN CARBOXYCHROMANOLS AND ANALOGS FOR USE AS ANTI-INFLAMMATORY AGENTS | ALOX12, ALOX5, PTGS1 | ALOX5 2/4885NR1I2 997/4885PPARG 541/4885 |
| US-20170296505-A1 | LONG-CHAIN CARBOXYCHROMANOLS AND ANALOGS FOR USE AS ANTI-INFLAMMATORY AGENTS | ALOX12, ALOX5, PTGS1 | ALOX5 2/4885NR1I2 997/4885PPARG 541/4885 |
| US-20050137253-A1 | Formulations and methods for treatment or amelioration of inflammatory conditions | ALOX15B, ALOX5, ALOX12 | ALOX5 2/4885NR1I2 1261/4885PPARG 43/4885 |
| US-20030100603-A1 | Tocopherol enriched compositions and amelioration of inflammatory symptoms | TTPA, TNNT2, GSR | ALOX5 35/4885NR1I2 823/4885PPARG 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.